KEYTRUDA Merck Sharp & Dohme (Australia) Pty Ltd
Product name
KEYTRUDA
Accepted date
Feb-2025
Active ingredients
pembrolizumab
Proposed indication
Keytruda (pembrolizumab) is indicated for patients with head and neck squamous cell carcinoma (HNSCC):
-as a preliminary treatment prior to surgery to remove the carcinoma.
-as a treatment for HNSCC in combination with
radiotherapy (with or without platinum-containing cancer drugs) followed by Keytruda treatment alone.
-as a preliminary treatment prior to surgery to remove the carcinoma.
-as a treatment for HNSCC in combination with
radiotherapy (with or without platinum-containing cancer drugs) followed by Keytruda treatment alone.
Application type
C (new indication)
Publication date
Feb-2025